GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (XPAR:BIM) » Definitions » Machinery, Furniture, Equipment

BioMerieux (XPAR:BIM) Machinery, Furniture, Equipment : €0 Mil (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is BioMerieux Machinery, Furniture, Equipment?

BioMerieux's Machinery, Furniture, Equipment for the quarter that ended in Dec. 2023 was €0 Mil.


BioMerieux Machinery, Furniture, Equipment Historical Data

The historical data trend for BioMerieux's Machinery, Furniture, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Machinery, Furniture, Equipment Chart

BioMerieux Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Machinery, Furniture, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioMerieux Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Machinery, Furniture, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 700.40 - - -

BioMerieux Machinery, Furniture, Equipment Calculation

Machinery, Furniture, Equipment represents those fixed assets specifically dealing with tools, equipment and office furniture.


BioMerieux (XPAR:BIM) Business Description

Traded in Other Exchanges
Address
Marcy l’Etoile, Lyon, FRA, 69280
BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

BioMerieux (XPAR:BIM) Headlines

No Headlines